ASIT biotech today announces the publication of a report by Kepler Cheuvreux, a leading independent European financial services company specialized in research, execution and advisory services.
Brussels, Belgium November 28, 2018 – 05.45 pm (CET) - ASIT Biotech (Euronext: ASIT - BE0974289218), a Belgian biopharmaceutical company specialized in allergy immunotherapy, today announces the publication of a report by Kepler Cheuvreux, a leading independent European financial services company specialized in research, execution and advisory services.
Thierry Legon, CEO of ASIT biotech, commented: ”With the recent addition of Kepler Cheuvreux, ASIT biotech is now covered by 5 leading financial analysts (others being KBC Securities, Bryan Garnier & Co., Société Générale-Gilbert Dupont, Edison Research) which confirms the rising interest of the financial community for ASIT biotech’s unique approach in the field of allergy immunotherapy, a growing indication with a multi-billion Euro market potential. They are globally aligned on their valuation of our lead asset to treat grass-pollen Allergic Rhinitis, gp-ASIT+™, currently in Phase III with peak sales estimates between €300 and 500 million, as well as on the potential of our 2 other product candidates for house dust mites and peanut allergies with cumulative peak sales estimated above €1 billion *.”
* This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country. ASIT biotech have agreed on a service for the production and distribution of financial analyses with Edison and Bryan Garnier & Co.
***
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™). These products could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.
ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
ASIT biotech
Thierry Legon
CEO
Phone nb.: +32 2 264 03 90
Email: investors@asitbiotech.com
NewCap
Dusan Oresansky / Pierre Laurent
Media and Investor Relations - France
Phone nb.: +33 1 44 71 94 92
Email: asitbiotech@newcap.eu
Comfi
Laure-Eve Monfort
Media Relations - Belgium
Phone nb.: +32 2 290 90 93
Email: mo
